TUTakahide Uchimura

Takahide Uchimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takahide Uchimura has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Haruki Kinoshita

    Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan

    3 shared publications
  • Motohiro Kato

    Pre‐clinical Research Department, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan

    3 shared publications
  • Kimitoshi Saito

    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Gotemba, Shizuoka, Japan

    2 shared publications
  • Yoshiaki Nabuchi

    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Gotemba, Shizuoka, Japan

    2 shared publications
  • Rie Shiokawa

    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Gotemba, Shizuoka, Japan

    1 shared publication
  • Shinichi Arai

    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Gotemba, Shizuoka, Japan

    1 shared publication

Latest Publications

  • Prediction of human blood‐to‐plasma drug concentration ratio

    by Takahide Uchimura, Motohiro Kato, Tomohisa Saito, Haruki Kinoshita

    The objective of this study was to predictRb(blood/plasma ratio) in humans using a simple method. Human and ratRband free fraction in plasma (fp) values were obtained from the literature. The ratio of total red blood cell concentration to the free concentration in plasma (Kb) was calculated usingfpandRb. Four methods were used for the prediction ofRb: (A) use of ratRb; (B) use ofRbcalculated from ratKband humanfp; (C) correlation of human log ((1−fp)/fp) and human logKb; and (D) correlation of logDwith human logKb. TheRbof 96 compounds in humans ranged from 0.52 to 2.00, with an average of 0.89. A significant correlation was observed among human logKb, human log ((1−fp)/fp), and logD; however, no obvious correlation was observed among humanRb, human log ((1−fp)/fp), and logD. The errors within 1.25‐fold for methods A–D were 68.3%, 77.6%, 61.5% and 64.8%, respectively. All predictive methods considered here were superior to the use of the average value of humanRborRb=1. RatRbcorrected by humanfpimproved the accuracy of the prediction. Method B was the most accurate of the four methods. Copyright © 2010 John Wiley & Sons, Ltd.


  • Estimation of serum protein binding of compounds metabolized in serum using matrix inhibition

    by Takahide Uchimura, Motohiro Kato, Rie Shiokawa, Yoshiaki Nabuchi, Kimitoshi Saito, Haruki Kinoshita


  • New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition

    by Takahide Uchimura, Motohiro Kato, Tatsuhiko Tachibana, Shinichi Arai, Yoshiaki Nabuchi, Kimitoshi Saito, Haruki Kinoshita

    The purpose of this study was to develop a method for estimating the hepatic clearance (CLh) without using a protein binding test. This method allows the simultaneous evaluation of the intrinsic hepatic clearance (CLint) with a correction for microsomal binding, and the free fraction in the serum (fu). It uses the decrease in metabolic velocity achieved by decreasing the free fraction of a compound in the incubation mixture (fuinc) by the addition of serum, and by changing the microsomal protein concentration. This method is denoted as the ‘matrix inhibition method’, because it uses the inhibition of the metabolic velocity by the incubation matrix. The metabolic rates of eight compounds (diazepam, imipramine, warfarin, and compounds A–E) were evaluated under several incubation conditions using rat serum and microsomes. The correlation ofCLintevaluated using the method and using equilibrium dialysis after theCLintwas corrected for microsomal binding wasr = 0.968. The correlation offu · CLintwasr = 0.996. Although the method required a high enoughfuandfumicrosomesdifference among the reaction conditions for each compound, it could evaluateCLintandfusimultaneously and easily by adding additional reaction conditions to the metabolic stability tests performed in ADME screening. Copyright © 2007 John Wiley & Sons, Ltd.